The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model
International Journal of Molecular Sciences · 28.06.2026 · 27 (13) · 5828
DOI: 10.3390/ijms27135828 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.06.2026. Verfasst von Yoko Kuba-Fuyuno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan. Hauptthemen laut MEDLINE: Keratinocytes, Lupus Erythematosus, Cutaneous, Stilbenes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Health Labour and Welfare, Health, Labour and Welfare Policy Research Grants on Food Safety Program.
Abstract (Originalsprache)
Cutaneous lupus erythematosus (CLE) is an autoimmune disease in which type I interferon (IFN) has been well-established as a central pathogenic factor. It presents with diverse cutaneous manifestations that markedly impair patients’ quality of life. Therapeutic options for CLE remain limited and are often insufficient, highlighting the need for novel treatment strategies. The aryl hydrocarbon receptor (AHR) is a transcription factor that modulates immune responses and has recently attracted attention as a potential therapeutic target for autoimmune diseases. We previously confirmed that treatment of normal human epidermal keratinocytes with IFNα and Poly I:C upregulated the expression of the CLE-like inflammatory cytokines IFNκ, CXCL10, and IL6, as well as the B-cell activating factor. In the present study, we demonstrated by quantitative PCR and Western blotting that pretreatment with the AHR agonist tapinarof suppressed the upregulation of IFNκ and CXCL10. Mechanistically, we demonstrated that tapinarof suppresses IFNκ expression by inhibiting STAT1 phosphorylation in an AHR-dependent manner, thereby attenuating the nuclear translocation of ISGF3. Overall, we show that tapinarof suppresses CLE-like inflammation in human keratinocytes in an AHR-dependent manner, suggesting that it may represent a novel therapeutic agent for CLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan.
- Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan.
ORCID-Profile: Yoko Kuba-Fuyuno, Takeshi Nakahara
Förderung
- Japan Society for the Promotion of Science
- Ministry of Health Labour and Welfare
- Health, Labour and Welfare Policy Research Grants on Food Safety Program
- JSPS
Zitieren
APA
Kuba-Fuyuno, Y., Tsuji, G., Kido-Nakahara, M., Yamamura, K., Sakai, S., & Nakahara, T. (2026). The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model. International Journal of Molecular Sciences, 27(13), 5828. https://doi.org/10.3390/ijms27135828
Vancouver
Kuba-Fuyuno Y, Tsuji G, Kido-Nakahara M, Yamamura K, Sakai S, Nakahara T. The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model. International Journal of Molecular Sciences. 2026;27(13):5828. doi:10.3390/ijms27135828
BibTeX
@article{KubaFuyuno2026,
author = {Kuba-Fuyuno, Yoko and Tsuji, Gaku and Kido-Nakahara, Makiko and Yamamura, Kazuhiko and Sakai, Sawako and Nakahara, Takeshi},
title = {The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5828},
doi = {10.3390/ijms27135828}
}
EUVIMED